Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DFPP-derived Antibodies for Early COVID-19 Pneumonia
NCT04418531Withdrawn
- Start
- Jun 2020
- Primary completion
- Sep 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Open-label, single-arm trial of anti-COVID-19 immune globulin in COVID-19 pneumonia. Primary endpoint: Time to weaning of oxygen support. Planned start Jun 2020; status: withdrawn.
02
Drugs
anti-COVID-19 immune globulin
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04418531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04418531.